Hidradenitis suppurativa and risk for development of Clostridium difficile colitis

Int J Dermatol. 2020 Jun;59(6):e218-e219. doi: 10.1111/ijd.14787. Epub 2020 Feb 3.

Authors

Alexis B Lyons¹, Hisham Kaddurah², Anjelica Peacock², Raheel Zubair³, Gautham Vellaichamy⁴, Paige Norwick⁵, Mayur Ramesh¹, Gordon Jacobsen¹, Iltefat H Hamzavi¹

Affiliations

¹ Department of Dermatology, Henry Ford Hospital, Detroit, MI, USA.
² Department of Internal Medicine, St. Mary Mercy Hospital, Livonia, MI, USA.
³ Department of Dermatology, Broward Health, Ft. Lauderdale, FL, USA.
⁴ Wayne State School of Medicine, Detroit, MI, USA.
⁵ Department of Internal Medicine, Mercy Health, Grand Rapids, MI, USA.

PMID: 32010962
DOI: 10.1111/ijd.14787

No abstract available

Publication types

Letter

MeSH terms

Anti-Bacterial Agents / adverse effects*
Case-Control Studies
Clostridioides difficile / immunology
Clostridioides difficile / isolation & purification*
Enterocolitis, Pseudomembranous / epidemiology*
Enterocolitis, Pseudomembranous / immunology
Enterocolitis, Pseudomembranous / microbiology
Hidradenitis Suppurativa / complications*
Hidradenitis Suppurativa / drug therapy
Hidradenitis Suppurativa / immunology
Humans
Incidence
Retrospective Studies
Risk Assessment / statistics & numerical data
Warts / complications*
Warts / immunology

Substances

Anti-Bacterial Agents